

AD-A085 977

VIRGINIA MASON RESEARCH CENTER SEATTLE WASH  
CONTROL OF THE INFLAMMATORY PROCESS.(U)  
APR 80 J C HOUCK

F/6 6/5

UNCLASSIFIED


N00014-77-C-0262

NL

101  
80



END  
DATE  
FILMED  
8 80  
DTIC



MICROCOPY RESOLUTION TEST CHART  
NATIONAL BUREAU OF STANDARDS 1963 A

LEVEL

13  
H

ANNUAL REPORT

OFFICE OF NAVAL RESEARCH

ADA 085977

CONTRACT NO.

15 N00014-77-C-0262 / Mod. # 202-134

TITLE:

6 CONTROL OF THE INFLAMMATORY PROCESS

Date of Project:

April 1, 1979 through March 31, 1980

INVESTIGATOR:

10 John C. Houck, Ph.D.  
Director  
Virginia Mason Research Center  
1000 Seneca Street  
Seattle, Washington 98101

12/11

*Final report submitted April 1, 1980*

4/1/80  
Date

*John C. Houck*  
John C. Houck, Ph.D., Principal Investigator

11 4 Apr 80

DTIC  
SELECTED  
S JUN 23 1980  
A

DISTRIBUTION STATEMENT A  
Approved for public release  
Distribution Unlimited

PROCESSED

80 4 8 034

## INSTRUCTIONS FOR PREPARATION OF REPORT DOCUMENTATION PAGE

**RESPONSIBILITY.** The controlling DoD office will be responsible for completion of the Report Documentation Page, DD Form 1473, on all technical reports prepared by or for DoD organizations.

**CLASSIFICATION.** Since this Report Documentation Page, DD Form 1473, is used in preparing announcements, bibliographies, and abstracts, it should be unclassified if possible. If a classification is required, identify the classified items on the page by the appropriate symbol.

### COMPLETION GUIDE

General. Make Blocks 1, 4, 5, 6, 7, 11, 13, 15, and 16 agree with the corresponding information on the report cover. Leave Blocks 2 and 3 blank.

**Block 1.** Report Number. Enter the unique alphanumeric report number shown on the cover.

**Block 2.** Government Accession No. Leave Blank. This space is for use by the Defense Documentation Center.

**Block 3.** Recipient's Catalog Number. Leave blank. This space is for the use of the report recipient to assist in future retrieval of the document.

**Block 4.** Title and Subtitle. Enter the title in all capital letters exactly as it appears on the publication. Titles should be unclassified whenever possible. Write out the English equivalent for Greek letters and mathematical symbols in the title (see "Abstracting Scientific and Technical Reports of Defense-sponsored RDT/E," AD-667 000). If the report has a subtitle, this subtitle should follow the main title, be separated by a comma or semicolon if appropriate, and be initially capitalized. If a publication has a title in a foreign language, translate the title into English and follow the English translation with the title in the original language. Make every effort to simplify the title before publication.

**Block 5.** Type of Report and Period Covered. Indicate here whether report is interim, final, etc., and, if applicable, inclusive dates of period covered, such as the life of a contract covered in a final contractor report.

**Block 6.** Performing Organization Report Number. Only numbers other than the official report number shown in Block 1, such as series numbers for in-house reports or a contractor/grantee number assigned by him, will be placed in this space. If no such numbers are used, leave this space blank.

**Block 7.** Author(s). Include corresponding information from the report cover. Give the name(s) of the author(s) in conventional order (for example, John R. Doe or, if author prefers, J. Robert Doe). In addition, list the affiliation of an author if it differs from that of the performing organization.

**Block 8.** Contract or Grant Number(s). For a contractor or grantee report, enter the complete contract or grant number(s) under which the work reported was accomplished. Leave blank in in-house reports.

**Block 9.** Performing Organization Name and Address. For in-house reports enter the name and address, including office symbol, of the performing activity. For contractor or grantee reports enter the name and address of the contractor or grantee who prepared the report and identify the appropriate corporate division, school, laboratory, etc., of the author. List city, state, and ZIP Code.

**Block 10.** Program Element, Project, Task Area, and Work Unit Numbers. Enter here the number code from the applicable Department of Defense form, such as the DD Form 1498, "Research and Technology Work Unit Summary" or the DD Form 1634, "Research and Development Planning Summary," which identifies the program element, project, task area, and work unit or equivalent under which the work was authorized.

**Block 11.** Controlling Office Name and Address. Enter the full, official name and address, including office symbol, of the controlling office. (Equates to funding/sponsoring agency. For definition see DoD Directive 5200.20, "Distribution Statements on Technical Documents.")

**Block 12.** Report Date. Enter here the day, month, and year or month and year as shown on the cover.

**Block 13.** Number of Pages. Enter the total number of pages.

**Block 14.** Monitoring Agency Name and Address (if different from Controlling Office). For use when the controlling or funding office does not directly administer a project, contract, or grant, but delegates the administrative responsibility to another organization.

**Blocks 15 & 15a.** Security Classification of the Report: Declassification/Downgrading Schedule of the Report. Enter in 15 the highest classification of the report. If appropriate, enter in 15a the declassification/downgrading schedule of the report, using the abbreviations for declassification/downgrading schedules listed in paragraph 4-207 of DoD 5200.1-R.

**Block 16.** Distribution Statement of the Report. Insert here the applicable distribution statement of the report from DoD Directive 5200.20, "Distribution Statements on Technical Documents."

**Block 17.** Distribution Statement (of the abstract entered in Block 20, if different from the distribution statement of the report). Insert here the applicable distribution statement of the abstract from DoD Directive 5200.20, "Distribution Statements on Technical Documents."

**Block 18.** Supplementary Notes. Enter information not included elsewhere but useful, such as: Prepared in cooperation with . . . Translation of (or by) . . . Presented at conference of . . . To be published in . . .

**Block 19.** Key Words. Select terms or short phrases that identify the principal subjects covered in the report, and are sufficiently specific and precise to be used as index entries for cataloging, conforming to standard terminology. The DoD "Thesaurus of Engineering and Scientific Terms" (TEST), AD-672 000, can be helpful.

**Block 20.** Abstract. The abstract should be a brief (not to exceed 200 words) factual summary of the most significant information contained in the report. If possible, the abstract of a classified report should be unclassified and the abstract to an unclassified report should consist of publicly-releasable information. If the report contains a significant bibliography or literature survey, mention it here. For information on preparing abstracts see "Abstracting Scientific and Technical Reports of Defense-Sponsored RDT&E," AD-667 000.

## ABSTRACT

1. We have purified the factor released by lung cells during their cultivation *in vitro* which permit the mitotic activity of alveolar macrophages. This factor has a molecular weight of 68,000 daltons with an isoelectric point of 4.2 and is in equilibrium with as much as 20% of the total molecular species as dimers, trimers and tetramers.

2. This activity appears to possess the ability to inhibit trypsin and elastase but not chymotrypsin.

3. We have purified to electrophoretic homogeneity a macromolecular factor from aqueous extracts of lung which has a molecular weight of 82,000 daltons and also an isoelectric point of pH 4.2. This factor increases the permeability of the microcirculation in rat skin *in vivo* by degranulating mast cells so that they release histamine.

4. This permeability factor is inhibited by antihistamines and also by pre-mixture with pepstatin, an acid protease inhibitor which also is chemotactic for polymorphonuclear leukocytes *in vitro*. The purified permeability factor from lung has no proteolytic activity at any pH against either synthetic or natural substrates, however.

5. This permeability producing activity appears to be concentrated in the lysosomes of alveolar macrophages.

6. Pepstatin also possesses the ability to inhibit the permeability factor found in testicular hyaluronidase preparations; this permeability factor also degranulates mast cells and obviously pepstatin is an important inhibitor of mast cell degranulation, and hence, histamine release.

7. We have isolated and partially purified a macromolecule weighing 80,000 daltons with an isoelectric point of around neutrality, which effectively paralyzes lymphocyte transformation and thereby inhibits lymphocyte function *in vitro* and *in vivo*. This molecule is mixed with large amounts of exotoxin A produced by the *Pseudomonas aeruginosa* from which it is derived, and which is difficult to remove by large-scale purification techniques required to accumulate sufficient material to study its ability to inhibit lymphocyte function *in vivo*.

8. Relatively small amounts of this material, when injected on alternate days I.P. into C-57 mice receiving Balb-6 skin grafts, will defer and delay the normal rejection of this graft over a histoincompatibility barrier.

Accession For	
NOIS GARDI	
NOIS TAX	
NOIS TAX	
NOIS TAX	
<i>Letter on file</i>	
A	

## INTRODUCTION:

For a number of years we have been interested in isolating, purifying and characterizing various important chemical messengers of the inflammatory process. Many of these factors have been derived from transformed lymphocytes such as Macrophage Migration Inhibitory Factor, lymphotactin, Skin Reactive Factor, etc. On the basis of these results we have put together the following picture of the inflammatory process, whether precipitated by antigens or by acute injury;

- 1) An increased permeability of the microcirculation flooding the injured area with various elements of the circulation, including complement as a first line of defense. The increased permeability for the most part appears to result from the degranulation of the mast cell which functions much like a fire alarm, scattered extensively throughout the connective tissue and hence, throughout the whole organism and which is turned on by a wide variety of insults;
- 2) The release of various derivatives of arachidonic acid, such as the various prostaglandins, which also increase the permeability of the microcirculation as well as serve as mildly chemotactic stimulants for the mobilization of polymorphonuclear leukocytes into the injured area. This chemotactic mobilization is also supported, and perhaps even dominated, by the release of small peptide C5A from the activation either by the indirect pathway, or directly, of the complement chain;
- 3) In Immunologically mediated inflammation a very small number of lymphocytes which will respond to an antigenic stimulus by transformation, release a factor which we call lymphotactin, which is specifically chemotactic for T-lymphocytes. In this fashion a larger number of T cells are brought into propinquity with challenging antigen and thus become sophisticated. Thus, by amplifying the response through the use of chemotactic messengers, a recruitment of a large number of naive lymphocytes can occur.

It is our position that by examining some of the control mechanisms involved in the processes described above lies the hope for the eventual control of the inflammatory process. Specifically, we have addressed ourselves to the release of permeability factor, particularly from macrophage lysosomes and mast cells, and the inhibition of lymphocyte transformation and hence, immune function.

## MATERIALS AND METHODS:

Routine techniques of the extraction of tissues and their fractionation via ultrafiltration and isoelectric focussing have been described in the listed publications resulting from this work during 1979. Assay procedures in vivo involve the semi-quantitative determination of the "blueing reaction" in the skin of Sprague-Dawley rats as have been described previously ( 1 ). Inhibition of lymphocyte function as determined from the inhibition of thymidine uptake and visual qualitative evidence of transformation of small lymphocytes into large lymphoblasts in two-way Mixed Lymphocyte Culture using spleen lymphocytes obtained from C-57 and BALB-6 mice in microwells ( 2 ). Macrophage proliferation was also

studied by direct cell counting of alveolar washout macrophages, which are phagocytic adherent mononuclear cells collected in Leighton tubes in vitro, and confirmed by quantitative studies of the amount of <sup>3</sup>H-thymidine incorporated into the DNA of these cells (3).

*Pseudomonas aeruginosa* was obtained from a particular patient as has been described in previous reprints and also as described in an enclosed reference (4). These bacteria are harvested by centrifugation and after rinsing, are smashed by high-speed vibration with microbeads. The supernatant material is removed by extraction into saline and after clarification by centrifugation the soluble fraction is subjected to G-200 molecular exclusion column chromatography to separate the inhibitory principle from various proteases which will destroy it. After collecting the roughly 80,000 dalton-sized inhibitor, it is dialyzed against large volumes of acetate buffer at pH 4.5 and almost all of the exotoxin produced by this bacteria is precipitated at its isoelectric point of 4.5. The supernatant fraction is then harvested, dialyzed exhaustively against water and lyophilized. This material is soluble in phosphate buffered saline contain Penn-strep, and it is in this form that it is injected into mice I.P. for studies of inhibition of skin graft rejection.

## RESULTS

As described in the enclosed references (5) after membrane ultrafiltration to collect the materials in excess of 30,000 daltons and isoelectric focussing to collect the materials with an isoelectric point of pH 4.2, the bulk of the components found in the supernatant medium from the cultivation of mouse lung cells which would support the proliferation of mouse alveolar washout macrophages in medium F-12 containing 10% fetal calf serum, was accomplished. In acrylamide gel electrophoresis at two different pH, this material showed a pattern appropriate to the bulk of the material being a monomer which in SDS electrophoresis is 68,000 daltons, which is equilibrium with smaller amounts of dimer, trimer and tetramer forms of the activity. All of these forms are active to support mitosis and also are capable of inhibiting trypsin and elastase, but not chymotrypsin. This finding is remarkable in that in general, proteases are supposed to promote proliferation and here a proliferation factor is, in fact, inhibiting proteolytic activity.

Aqueous extracts of lung tissue from both calf and human contain a number of factors which increase the permeability of the microcirculation of rat skin in vivo (6). One of these factors is of small molecular weight and is probably spermine. However, another factor which we have purified to electrophoretic homogeneity at three different pH has a molecular weight of 82,000 daltons and an isoelectric point of 4.2. This factor apparently works by the liberation of histamine, presumably by the accumulating degranulation of mast cells. This factor appears to be concentrated particularly in macrophages and in the lysosomal compartment of whole lung tissue extracts. Thus, we propose that when macrophages in the alveolar spaces are actively engaged in phagocytosis, they quote "drool" a macromolecule which, in turn, can release histamine from mast cells and thereby increase the permeability of the microcirculation so as to allow complement to extravasate into the area to assist in the defense of the tissue. This in turn suggests that the treatment of pulmonary edema with antihistamines could be a very clinically useful therapeutic regimen.

The fact that pepstatin (a bizarre pentapeptide from fermentation processes known to inhibit acid proteolytic activity) should inhibit this phenomenon is quite interesting; particularly since purified permeability factor from lung has no proteolytic activity at any pH against either synthetic or natural substrates. This suggests that the possibility of pepstatin inhibiting enzymes essential to the degranulation of mast cells which exist on the surface of the mast cell, could be an important mechanism. Further, crude hyaluronidase or highly purified hyaluronidase is contaminated by a factor which leads to the increase in the permeability of the microcirculation, again by degranulation of mast cells. Again, this factor from testicular extracts is inhibited by pepstatin! However, this factor when purified has no proteolytic activity at all at any pH against native or synthetic substrates. Thus, once again the possibility of pepstatin inhibiting degranulation of mast cells by inhibition of surface enzymes is raised.

Finally, in experiments I have published, we have effected the degranulation of mast cells in rats by the use of 48/80, a compound whose mechanism is known to involve the degranulation of mast cells and the action of this material to increase the blueing reaction in vivo in rats is antagonized by pepstatin, in vivo. Thus, it would appear that certain peptides are capable of inhibiting the release of histamine from mast cells and hence, inhibiting the inflammatory process. We are currently interested in the possibility of other chemotactic peptides (since pepstatin is also known to be chemotactic in vitro and in vivo) which might be incapable of inhibiting mast cell degranulation in vivo.

In addition to the possibility of controlling permeability increases by virtue of peptides inhibiting the release of histamine from mast cells, the other possibility controlling the inflammatory process, particularly in terms of chronic or immunologically mediated inflammation, proceeds from the ability to inhibit lymphocyte transformation in vitro and hence, lymphocyte function in vivo. Cultivating large amounts of a *Pseudomonas aeruginosa* strain obtained from a patient who had demonstrated remarkable resistance to graft rejection, we have purified (as indicated above) a macromolecule with a neutral isoelectric point which apparently can paralyze lymphocytes in vitro and in vivo. C-57 mice receive BALB/6 skin grafts in vivo normally will reject these skin grafts in 11 to 13 days. However, if these animals have received the partially purified bacterial inhibitor product, they are incapable of mounting as profound a rejection response to histoincompatible skin grafts and so these grafts survive for at least twice the normal period, or until the injections are terminated. Shortly thereafter they are rejected in vivo. It is this latter phenomenology that we propose to investigate during the coming year.

#### FUTURE GOALS

We hope to be able to accumulate sufficient amounts of reasonably purified bacterial inhibitor of lymphocyte transformation and function so as to demonstrate the efficacy of this material in vivo. This will require the services of both a technician and a Research Fellow to effect the cultivation, isolation and the purification of the inhibitory macromolecules from this strain of *Pseudomonas aeruginosa*, as well as surgical technician to perfect the skin graft studies which are necessary to demonstrate in vivo efficacy.

References:

1. Lykke, A.W.J., D.A. Willoughby and J.C. Houck. Effects of cortisol released cutaneous protease upon the permeability of the micro-circulation. *J. Invest. Dermatol.* 48: 318 (1967).
2. Houck, J.C. and C.M. Chang. Permeability factor contaminating hyaluronidase preparations. *Inflammation*, Vol. 3, No. 4, pp 447-451 (1979).
3. Naum, Y., C.M. Chang and J.C. Houck. Pulmonary Macrophage Growth Factor. *Inflammation*, Vol. 3, No. 3:253-260 (1979)
4. Houck, J.C. The biochemistry of a bacterial inhibitor specific for the inhibition of T and B cell lymphocyte function in vitro and in vivo. *Int. J. Tissue Reactions* 1:1 (1979).
5. Houck, J.C., J.M. Gleisner and C.M. Chang. Macromolecular, anionic, pulmonary permeability factor. *Inflammation*, Vol. 3, No. 4:453-462 (1979).

OFFICE OF NAVAL RESEARCH  
BIOLOGICAL SCIENCES DIVISION  
BIOPHYSICS PROGRAM, Code 444  
DISTRIBUTION LIST FOR TECHNICAL, ANNUAL AND FINAL REPORTS

Number of Copies

- (13) Administrator, Defense Documentation Center  
Cameron Station  
Alexandria, Virginia 22314
- (6) Director, Naval Research Laboratory  
Attention: Technical Information Division  
Code 2627  
Washington, D. C. 20375
- (6) Office of Naval Research  
Attention: Code 102IP (ONRL DOC)  
800 N. Quincy Street  
Arlington, Virginia 22217
- (3) Office of Naval Research  
Biophysics Program  
Code 444  
Arlington, Virginia 22217
- (1) Commanding Officer  
Naval Medical Research and Development Command  
National Naval Medical Center  
Bethesda, Maryland 20014
- (1) Chief, Bureau of Medicine and Surgery  
Department of the Navy  
Washington, D. C. 20375
- (2) Technical Reference Library  
Naval Medical Research Institute  
National Naval Medical Center  
Bethesda, Maryland 20014
- (1) Office of Naval Research Branch Office  
Building 114, Section D  
666 Summer Street  
Boston, Massachusetts 02210
- (1) Office of Naval Research Branch Office  
536 South Clark Street  
Chicago, Illinois 60605

Enclosure (3)

- (1) Office of Naval Research Branch Office  
1030 East Green Street  
Pasadena, California 91106
- (1) Commanding Officer  
Naval Medical Research Unit No. 2  
Box 14  
APO San Francisco 96263
- (1) Commanding Officer  
Naval Medical Research Unit No. 3  
FPO New York 09527
- (1) Officer in Charge  
Submarine Medical Research Laboratory  
Naval Submarine Base, New London  
Groton, Connecticut 06342
- (1) Scientific Library  
Naval Aerospace Medical Research Institute  
Naval Aerospace Medical Center  
Pensacola, Florida 32512
- (1) Commanding Officer  
Naval Air Development Center  
Attn: Aerospace Medical Research Department  
Warminster, Pennsylvania 18974
- (1) DIRECTOR  
Naval Biosciences Laboratory  
Building 844  
Naval Supply Center  
Oakland, California 94625
- (1) Commander, Army Research Office  
P. O. Box 12211  
Research Triangle Park  
North Carolina 27709
- (1) DIRECTORATE OF LIFE SCIENCES  
Air Force Office of Scientific Research  
Bolling Air Force Base  
Washington, D. C. 20332
- (1) Commanding General  
Army Medical Research and Development Command  
Forrestal Building  
Washington, D. C. 20314

(1)

Department of the Army  
U. S. Army Science and  
Technology Center - Far East  
APO San Francisco 96328

(1)

Assistant Chief for Technology  
Office of Naval Research, Code 200  
800 N. Quincy Street  
Arlington, Virginia 22217

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER N00014-77-C-0262 Mod. #202-134	2. GOVT ACCESSION NO. AD-A085977	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) CONTROL OF THE INFLAMMATORY PROCESS	5. TYPE OF REPORT & PERIOD COVERED Annual 4/1/79 - 3/31/80	
	6. PERFORMING ORG. REPORT NUMBER	
7. AUTHOR(s) John C. Houck, Ph.D.	8. CONTRACT OR GRANT NUMBER(s) N00014-77-C-0262	
9. PERFORMING ORGANIZATION NAME AND ADDRESS Virginia Mason Research Center 1000 Seneca Street, Seattle, WA 98101	10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS	
11. CONTROLLING OFFICE NAME AND ADDRESS R. J. Bowls, Assoc. Director for Finance & Admin. Virginia Mason Research Center 1000 Seneca Street, Seattle, WA 98101	12. REPORT DATE April 4, 1980	
	13. NUMBER OF PAGES 6	
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office) N/A	15. SECURITY CLASS. (of this report)	
	15a. DECLASSIFICATION/DOWNGRADING SCHEDULE	
16. DISTRIBUTION STATEMENT (of this Report) Annual Report		
<div style="border: 1px solid black; padding: 5px; display: inline-block;">           DISTRIBUTION STATEMENT A            Approved for public release            Distribution Unlimited         </div>		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number)  Inflammation		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number)  We have purified the factor released by lung cells during their cultivation in vitro which permit the mitotic activity of alveolar macrophages. This factor has a molecular weight of 68,000 daltons with an isoelectric point of 4.2 and is in equilibrium with as much as 20% of the total molecular species as dimers, trimers and tetramers. →		

20. continued

2. This activity appears to possess the ability to inhibit trypsin and elastase but not chymotrypsin.

3. We have purified to electrophoretic homogeneity a macromolecular factor from aqueous extracts of lung which has a molecular weight of 82,000 daltons and also an isoelectric point of pH 4.2. This factor increases the permeability of the microcirculation in rat skin in vivo by degranulating mast cells so that they release histamine.

4. This permeability factor is inhibited by antihistamines and also by premixture with pepstatin, an acid protease inhibitor which also is chemotactic for polymorphonuclear leukocytes in vitro. The purified permeability factor from lung has no proteolytic activity at any pH against either synthetic or natural substrates, however.

5. This permeability producing activity appears to be concentrated in the lysosomes of alveolar macrophages.

6. Pepstatin also possesses the ability to inhibit the permeability factor found in testicular hyaluronidase preparations; this permeability factor also degranulates mast cells and obviously pepstatin is an important inhibitor of mast cell degranulation, and hence, histamine release.

7. We have isolated and partially purified a macromolecule weighing 80,000 daltons with an isoelectric point of around neutrality, which effectively paralyzes lymphocyte transformation and thereby inhibits lymphocyte function in vitro and in vivo. This molecule is mixed with large amounts of exotoxin A produced by the *Pseudomonas aeruginosa* from which it is derived, and which is difficult to remove by large-scale purification techniques required to accumulate sufficient material to study its ability to inhibit lymphocyte function in vivo.

8. Relatively small amounts of this material, when injected on alternate days I.P. into C-57 mice receiving Balb-6 skin grafts, will defer and delay the normal rejection of this graft over a histoincompatible barrier.

